Natroba is owned by Parapro Llc.
Natroba contains Spinosad.
Natroba has a total of 2 drug patents out of which 0 drug patents have expired.
Natroba was authorised for market use on 18 January, 2011.
Natroba is available in suspension;topical dosage forms.
Natroba can be used as the product composition (natroba) is for the topical treatment of human scabies mite infestations by melting and delivering the active ingredient, spinosad, to the stratum corneum where scabies mites live and breed, natroba topical suspension is a pediculicide indicated for the topical treatment of head lice infestation in patients six (6) months of age and older..
The generics of Natroba are possible to be released after 25 November, 2033.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6063771 | PARAPRO LLC | Formulations for controlling human lice |
Jul, 2023
(5 months from now) | |
US9895388 | PARAPRO LLC | Methods and compositions useful for controlling cutaneous mites |
Nov, 2033
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Apr 28, 2024 |
Drugs and Companies using SPINOSAD ingredient
Market Authorisation Date: 18 January, 2011
Treatment: Natroba topical suspension is a pediculicide indicated for the topical treatment of head lice infestation in patients six (6) months of age and older.; The product composition (natroba) is for the topical treatment of human scabies mite infestations by melting and delivering the active ingredient, spinosad, to the stratum corneum where scabies mites live and breed
Dosage: SUSPENSION;TOPICAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic